Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 317-328

  Schwarz, Roderich E ^a,c   Smith, David D ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; STOMACH CANCER; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SEER PROGRAM; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 33846566815     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9218-2     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2):106-30.
2. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr., Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218(5):583-92.
3. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80(12):2333-41.
4. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000; 88(4):921-32.
5. Kodera Y, Yamamura Y, Shimizu Y, et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. J Am Coll Surg 1998; 187(6):597-603.
6. Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001; 84(12):1602-9.
7. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9(4):394-400.
8. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000; 232(3):362-71.
9. Roder JD, Bottcher K, Busch R, Wittekind C, Hermanek P, Siewert JR. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 1998; 82(4):621-31.
10. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995; 82(3):346-51.
11. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study [see comments]. Ann Surg 1998; 228(4):449-61.
12. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79(9-10):1522-30.
13. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group [see comments]. N Engl J Med 1999; 340(12):908-14.
14. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997; 84(11):1567-71.
15. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195(6):855-64.
16. Hartgrink HH, Van De Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized dutch gastric cancer group trial. J Clin Oncol 2004; 22(11):2069-77.
17. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005; 23(28):7114-24.
18. Surveillance, Epidemiology and End Results (SEER) Program: public use data (1973-2002). 2005 [accessed April 2005]; Available from: http://www.seer.cancer.gov.
19. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual, 6th edn. New York: Springer Verlag, 2002.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53:457-81.
21. Peto R, Pike MC. Conservatism in the approximation E(0-E)2/E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29:579-84.
22. Cox DR. Regression models and life tables. J R Stat Assoc 1972; 29:187-220.
23. Borie F, Plaisant N, Millat B, Hay JM, Fagniez PL. Appropriate gastric resection with lymph node dissection for early gastric cancer. Ann Surg Oncol 2004; 11(5):512-7.
24. de Manzoni G, Verlato G, Roviello F, et al. The new TNM classification of lymph node metastasis minimises stage migration problems in gastric cancer patients. Br J Cancer 2002; 87(2):171-4.
25. Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J.. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94(11):2862-6.
26. Lee HK, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP. Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 2001; 88(10):1408-12.
27. Dhar DK, Kubota H, Tachibana M, et al. Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients. Oncology 2000; 59(1):18-23.
28. Schwarz RE, Zagala-Nevarez K. Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur J Surg Oncol 2002; 28(3):214-9.
29. Callahan MA, Christos PJ, Gold HT, Mushlin AI, Daly JM. Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients. Ann Surg 2003; 238(4):629-36; discussion 36-39.
30. Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131(1):6-15.
31. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21(19):3647-50.
32. Peeters KC, Kattan MW, Hartgrink HH, et al. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 2005; 103(4):702-7.
33. Hartgrink HH, van de Velde CJ. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005; 90(3):153-65.
34. Hundley JC, Shen P, Shiver SA, Geisinger KR, Levine EA. Lymphatic mapping for gastric adenocarcinoma. Am Surg 2002; 68(11):931-5.
35. Song X, Wang L, Chen W, et al. Lymphatic mapping and sentinel node biopsy in gastric cancer. Am J Surg 2004; 187(2):270-3.
36. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10):725-30.